Babiker A, Warner S, Li X, et al. Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation. Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3—In this Article, the members of the NIH-Antimicrobial Resistance Outcomes Research Initiative have been updated. This correction has been made to the online version as of Nov 4, 2024 and will be made to the printed version.

中文翻译：

---

对柳叶刀感染疾病 2024 的更正;10 月 10 日在线发布。https://doi.org/10.1016/S1473-3099（24）00507-3


Babiker A， Warner S， Li X， et al. 2016 年至 2021 年美国 195 家医院β-内酰胺类药物治疗侵袭性 A 组链球菌感染患者的毒素抑制与克林霉素辅助治疗：一项具有靶向试验模拟的回顾性队列研究。柳叶刀感染疾病 2024;10 月 10 日在线发布。https://doi.org/10.1016/S1473-3099（24）00507-3—在本文中，NIH 抗菌素耐药性结果研究计划的成员已更新。此更正已于 2024 年 11 月 4 日对在线版本进行，并将对印刷版本进行。